Is Onconetix Inc (ONCO) overvalued? · P/E 0.0, rev $2.5M
Onconetix Inc (ONCO) is a biotechnology company listed on NASDAQ.
This page asks whether Onconetix Inc (ONCO) looks expensive on cached numbers — not a short thesis.
Latest reported ONCO revenue for 2024-12-31 was $2.5M. Net income was -$58.7M. Revenue was up 4217.3% from 2023-12-31 to 2024-12-31. ONCO currently screens at market cap $3.7M and trailing P/E 0.0.
ONCO currently screens at market cap $3.7M and trailing P/E 0.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ONCO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ONCO stock page for the full model, not this heading.
Not investment advice.